The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II/III randomized study of hyperfractionated radiotherapy with concomitant cetuximab versus concomitant chemotherapy in advanced nonmetastatic head and neck cancer: Preliminary report.
Khalid Al Saleh
No relevant relationships to disclose
Reham Safwat
No relevant relationships to disclose
Ahmed Bedair
No relevant relationships to disclose
Amany AL Basmy
No relevant relationships to disclose
H.S. Hooda
No relevant relationships to disclose
Jitendra Shete
No relevant relationships to disclose